Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multimodal Therapy for the Treatment of Sleep Disturbance in Patients With Cancer
NCT01628029Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2014
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of methylphenidate hydrochloride extended-release chewable tablet and melatonin in sleep disorder (8 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Pittsburgh Sleep Quality Index at Day 15. Started Jan 2014; status: active, not recruiting.
02
Drugs
methylphenidate hydrochloride extended-release chewable tabletmelatonin
03
Conditions
sleep disorder
Beyond the preview
Go deeper on NCT01628029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01628029.